Vicente Soriano

Summary

Affiliation: Hospital Carlos III
Country: Spain

Publications

  1. ncbi request reprint Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2b
    Eugenia Vispo
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    Antivir Ther 13:511-7. 2008
  2. ncbi request reprint Pharmacogenetics of antiretroviral therapy
    Pablo Barreiro
    Hospital Carlos III, Department of Infectious Diseases, Calle Sinesio Delgado 10, Madrid 28029, Spain
    Expert Opin Drug Metab Toxicol 10:1119-30. 2014
  3. pmc Optimizing management of treatment-naïve and treatment-experienced HIV+ patients: the role of maraviroc
    Eva Poveda
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    HIV AIDS (Auckl) 2:51-8. 2010
  4. pmc Role of atazanavir in the treatment of HIV infection
    Pablo Rivas
    Department of Infectious Diseases
    Ther Clin Risk Manag 5:99-116. 2009
  5. ncbi request reprint Dolutegravir, abacavir and lamivudine as HIV therapy
    José Vicente Fernández-Montero
    Hospital Carlos III, Department of Infectious Diseases, Madrid, Spain
    Expert Opin Pharmacother 15:1051-7. 2014
  6. doi request reprint Very late relapse after discontinuation of antiviral therapy for chronic hepatitis C
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    Antivir Ther 18:1033-5. 2013
  7. doi request reprint Emerging antiretroviral drugs
    José Vicente Fernández-Montero
    Hospital Carlos III, Department of Infectious Diseases, C Sinesio Delgado 10, Madrid, 28029, Spain
    Expert Opin Pharmacother 15:211-9. 2014
  8. ncbi request reprint Strategic use of lamivudine in the management of chronic hepatitis B
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain Electronic address
    Antiviral Res 100:435-8. 2013
  9. pmc Highlights from the 2012 International Symposium on HIV & Emerging Infectious Diseases (ISHEID): from cART management to the search of an HIV cure
    Alain Lafeuillade
    Department of Infectious Diseases, General Hospital, Toulon, France
    AIDS Res Ther 9:23. 2012
  10. doi request reprint Antiretroviral drug-related toxicities - clinical spectrum, prevention, and management
    Jose V Fernández-Montero
    Hospital Carlos III, Department of Infectious Diseases, C Sinesio Delgado 10, Madrid, 28029, Spain
    Expert Opin Drug Saf 12:697-707. 2013

Detail Information

Publications165 found, 100 shown here

  1. ncbi request reprint Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2b
    Eugenia Vispo
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    Antivir Ther 13:511-7. 2008
    ..Differences between PEG-IFN-alpha molecules could be more pronounced in HIV-coinfected individuals, in whom response to HCV treatment is impaired...
  2. ncbi request reprint Pharmacogenetics of antiretroviral therapy
    Pablo Barreiro
    Hospital Carlos III, Department of Infectious Diseases, Calle Sinesio Delgado 10, Madrid 28029, Spain
    Expert Opin Drug Metab Toxicol 10:1119-30. 2014
    ..Expert opinion: Integration of human genomic screening into HIV clinical management will be cost-effective, maximizing the benefit of drugs with the lowest risk of side effects for a given patient. ..
  3. pmc Optimizing management of treatment-naïve and treatment-experienced HIV+ patients: the role of maraviroc
    Eva Poveda
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    HIV AIDS (Auckl) 2:51-8. 2010
    ..However, the long-term consequences of using maraviroc must be carefully checked, given its particular mechanism of action, blocking a physiologic cell receptor...
  4. pmc Role of atazanavir in the treatment of HIV infection
    Pablo Rivas
    Department of Infectious Diseases
    Ther Clin Risk Manag 5:99-116. 2009
    ..Finally, ATV/r-based combinations have shown to be equivalent in terms of viral response to other PI/r-containing regimens, including LPV/r, in rescue interventions in patients failing other PI regimens (ie, studies AI424-045 and NADIS)...
  5. ncbi request reprint Dolutegravir, abacavir and lamivudine as HIV therapy
    José Vicente Fernández-Montero
    Hospital Carlos III, Department of Infectious Diseases, Madrid, Spain
    Expert Opin Pharmacother 15:1051-7. 2014
    ..The availability of this QD single pill represents a significant step further for a large number of HIV-infected persons...
  6. doi request reprint Very late relapse after discontinuation of antiviral therapy for chronic hepatitis C
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    Antivir Ther 18:1033-5. 2013
    ..Epidemiological and phylogenetic analyses supported very late HCV relapse instead of re-infection in two of them. This observation may have important implications in the pathogenesis and therapeutics of HCV infection. ..
  7. doi request reprint Emerging antiretroviral drugs
    José Vicente Fernández-Montero
    Hospital Carlos III, Department of Infectious Diseases, C Sinesio Delgado 10, Madrid, 28029, Spain
    Expert Opin Pharmacother 15:211-9. 2014
    ..All data on antiretrovirals in the most advanced development stages available in peer-reviewed journals or presented at international meetings has been reviewed...
  8. ncbi request reprint Strategic use of lamivudine in the management of chronic hepatitis B
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain Electronic address
    Antiviral Res 100:435-8. 2013
    ..A wise and strategic use of lamivudine may provide an opportunity to bring the benefit of therapy to large HBV-infected populations, while reducing health care costs. ..
  9. pmc Highlights from the 2012 International Symposium on HIV & Emerging Infectious Diseases (ISHEID): from cART management to the search of an HIV cure
    Alain Lafeuillade
    Department of Infectious Diseases, General Hospital, Toulon, France
    AIDS Res Ther 9:23. 2012
    ....
  10. doi request reprint Antiretroviral drug-related toxicities - clinical spectrum, prevention, and management
    Jose V Fernández-Montero
    Hospital Carlos III, Department of Infectious Diseases, C Sinesio Delgado 10, Madrid, 28029, Spain
    Expert Opin Drug Saf 12:697-707. 2013
    ..Due to the efficacious nature of combination antiretroviral therapy in most drug-adherent patients, the concerns on the safety profile of these lifelong medicines have attracted great attention...
  11. doi request reprint Update on HIV/HCV coinfection
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, Calle Sinesio Delgado 10, Madrid 28029, Spain
    Curr HIV/AIDS Rep 10:226-34. 2013
    ....
  12. doi request reprint Hepatitis B in HIV-infected patients
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, Calle Sinesio Delgado 10, Madrid 28029, Spain
    Clin Liver Dis 17:489-501. 2013
    ....
  13. ncbi request reprint The changing epidemiology of liver disease in HIV patients
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    AIDS Rev 15:25-31. 2013
    ..Hepatitis E is largely unrecognized, despite being the major cause of acute viral hepatitis worldwide and occasionally leading to chronicity in immunosuppressed individuals...
  14. doi request reprint Hepatitis C therapy with HCV NS5B polymerase inhibitors
    Vincent Soriano
    Hospital Carlos III, Department of Infectious Diseases, Calle Sinesio Delgado 10, Madrid 28029, Spain
    Expert Opin Pharmacother 14:1161-70. 2013
    ..It has good tolerability and a robust barrier to resistance. In contrast, non-nucleoside analogs have low to moderate antiviral potency, a low barrier to resistance and inhibit only HCV genotype 1...
  15. doi request reprint The changing face of hepatitis C in the new era of direct-acting antivirals
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    Antiviral Res 97:36-40. 2013
    ..The future will probably see a progressive marginalization of residual HCV populations, with increasing over-representation of illegal immigrants, alcohol abusers, intravenous drug users and the mentally disabled...
  16. doi request reprint Pharmacokinetics of new oral hepatitis C antiviral drugs
    Eugenia Vispo
    Hospital Carlos III, Infectious Diseases Department, Madrid, Spain
    Expert Opin Drug Metab Toxicol 9:5-16. 2013
    ..The development of new therapies with greater efficacy has been eagerly awaited but new challenges have emerged, with drug interactions being among the most challenging...
  17. doi request reprint Treatment of hepatitis C in patients infected with human immunodeficiency virus in the direct-acting antiviral era
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    Infect Dis Clin North Am 26:931-48. 2012
    ..First-generation DAAs will eventually be replaced by more potent, well-tolerated, and convenient agents. HIV/HCV co-infection will become restricted to individuals without proper access to health care...
  18. pmc Trends in the prevalence and distribution of HTLV-1 and HTLV-2 infections in Spain
    Ana Trevino
    Infectious Diseases Department, Hospital Carlos III, Calle Sinesio Delgado 10, Madrid 28029, Spain
    Virol J 9:71. 2012
    ..To assess the current seroprevalence of HTLV infection in Spain a national multicenter, cross-sectional, study was conducted in June 2009...
  19. ncbi request reprint Rilpivirine: a next-generation non-nucleoside analogue for the treatment of HIV infection
    José Vicente Fernández-Montero
    Hospital Carlos III, Department of Infectious Diseases, Calle Sinesio Delgado 10, 28029 Madrid, Spain
    Expert Opin Pharmacother 13:1007-14. 2012
    ..RPV is the latest NNRTI approved for the treatment of HIV infection. Along with its high efficacy and good safety profile, data on pharmacokinetics and drug interactions make RPV particularly attractive...
  20. doi request reprint Pharmacogenetics of hepatitis C
    Vincent Soriano
    Infectious Diseases Department, Hospital Carlos III, Madrid, Spain
    J Antimicrob Chemother 67:523-9. 2012
    ....
  21. pmc Tracing the HIV-1 subtype B mobility in Europe: a phylogeographic approach
    Dimitrios Paraskevis
    Katholieke Universiteit Leuven, Rega Institute for Medical Research, Minderbroederstraat 10, B 3000 Leuven, Belgium
    Retrovirology 6:49. 2009
    ..However the spatial diffusion of the epidemic from the perspective of the virus has not previously been traced...
  22. pmc Predictive factors of virological success to salvage regimens containing protease inhibitors in HIV-1 infected children
    Beatriz Larru
    Laboratorio de Inmuno Biología Molecular, Hospital General Universitario Gregorio Maranon, Madrid, Spain
    BMC Infect Dis 7:55. 2007
    ..The impact of HIV drug resistance mutations in salvage therapy has been widely investigated in adults. By contrast, data available of predictive value of resistance mutations in pediatric population is scarce...
  23. ncbi request reprint Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, Calle Sinesio Delgado 10, 28029 Madrid, Spain
    AIDS 21:1073-89. 2007
  24. ncbi request reprint Treatment failure with new hepatitis C drugs
    Vincent Soriano
    Hospital Carlos III, Department of Infectious Diseases, Calle Sinesio Delgado 10, Madrid 28029, Spain
    Expert Opin Pharmacother 13:313-23. 2012
    ..The addition of any of the two recently approved HCV protease inhibitors, boceprevir or telaprevir, to pegIFNα-RBV results in the cure for two-thirds of HCV genotype 1, interferon-naive patients...
  25. ncbi request reprint Treatment of chronic hepatitis B or C in HIV-infected patients with dual viral hepatitis
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, Madrid, 28029, Spain
    J Infect Dis 195:1181-3. 2007
    ..This information has important pathogenic implications and may influence therapeutic decisions...
  26. ncbi request reprint Chronic hepatitis C in HIV-infected patients: those who more need therapy are those who respond less
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    Infect Disord Drug Targets 6:57-88. 2006
    ..The relatively low efficacy of current anti-HCV medications and their low tolerability clearly indicated the need for new drugs with more potent and direct antiviral activity against HCV...
  27. ncbi request reprint Management of chronic hepatitis B and C in HIV-coinfected patients
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, Calle Sinesio Delgado 10, 28029 Madrid, Spain
    J Antimicrob Chemother 57:815-8. 2006
    ..Several guidelines have recently been released in response to this demand. In this article, we discuss the most critical issues highlighted in these documents...
  28. pmc Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses?
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, Sinesio Delgado 10, 28029 Madrid, Spain
    J Antimicrob Chemother 62:1-4. 2008
    ....
  29. ncbi request reprint Treatment of chronic hepatitis C in HIV-positive individuals: selection of candidates
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, C Sinesio Delgado, 10, 28029 Madrid, Spain
    J Hepatol 44:S44-8. 2006
    ....
  30. ncbi request reprint Complications in treating chronic hepatitis B in patients with HIV
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, Calle Sinesio Delgado 10, 28029 Madrid, Spain
    Expert Opin Pharmacother 6:2831-42. 2005
    ..Although response to IFN-alpha is poorer in HBV/HIV-coinfected patients compared with HBV-monoinfected individuals, the more potent pegylated forms of IFN-alpha have brought new hopes...
  31. ncbi request reprint New paradigms in the management of HIV and hepatitis C virus coinfection
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, Calle Sinesio Delgado 10, 28029 Madrid, Spain
    Curr Opin Infect Dis 18:550-60. 2005
    ..The bidirectional interferences between hepatitis C virus and HIV have clinical consequences and complicate the management of coinfected individuals...
  32. ncbi request reprint Failure of hepatitis C therapy in HIV-coinfected drug users is not due to a shift in hepatitis C virus genotype
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    J Infect Dis 192:1245-8. 2005
    ..Coinfection with distinct HCV genotypes is unlikely in former IDUs coinfected with HIV and does not explain the lower efficacy of HCV therapy in this population...
  33. ncbi request reprint Premature treatment discontinuation in HIV/HCV-coinfected patients receiving pegylated interferon plus weight-based ribavirin
    Vincent Soriano
    Hospital Carlos III, Madrid, Spain
    Antivir Ther 12:469-76. 2007
    ..Chronic hepatitis C therapy in HIV patients is often penalized by more frequent premature treatment discontinuations. It is unclear what the relative contribution of more adverse events and/or early virological failures are...
  34. ncbi request reprint Update on the treatment of chronic hepatitis C in HIV-infected patients
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    AIDS Rev 9:99-113. 2007
    ..g. tenofovir, lamivudine, or emtricitabine). Didanosine should never be coadministered with ribavirin due to potential life-threatening complications...
  35. ncbi request reprint Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, Calle Sinesio Delgado 10, 28029 Madrid, Spain
    J Antimicrob Chemother 61:200-5. 2008
    ..If proved, this strategy could be particularly attractive for the subset of patients with greater cardiovascular risk...
  36. doi request reprint Directly acting antivirals against hepatitis C virus
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    J Antimicrob Chemother 66:1673-86. 2011
    ..The complexity of HCV therapeutics has reached a point that presumably will lead to the birth of a new specialist, the HCV doctor...
  37. doi request reprint Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial
    Vicente Soriano
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    Antivir Ther 16:339-48. 2011
    ..Selection of first-line antiretroviral therapy requires consideration of efficacy as well as effects on lipids given the increased concern about cardiovascular risk in HIV-1 patients...
  38. doi request reprint Predictors of hepatitis B virus genotype and viraemia in HIV-infected patients with chronic hepatitis B in Europe
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    J Antimicrob Chemother 65:548-55. 2010
    ..Information about factors determining HBV genotype distribution and viraemia in HIV/HBV-co-infected patients is scarce...
  39. doi request reprint Viral hepatitis and HIV co-infection
    Vincent Soriano
    Infectious Diseases Department, Hospital Carlos III, Madrid, Spain
    Antiviral Res 85:303-15. 2010
    ..This article forms part of a special issue of Antiviral Research marking the 25th anniversary of antiretroviral drug discovery and development, Vol 85, issue 1, 2010...
  40. ncbi request reprint Hepatitis B in HIV patients: what is the current treatment and what are the challenges?
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    J HIV Ther 14:13-8. 2009
    ..At this time, most experts agree that early introduction of anti-HBV active HAART is the best strategy for the treatment of chronic hepatitis B in HIV patients, and Truvada must be part of the triple regimen...
  41. ncbi request reprint [Pharmacokinetics, interactions and mechanism of action of maraviroc]
    Vicente Soriano
    Departamento de Enfermedades Infecciosas, Hospital Carlos III, Madrid, Espana
    Enferm Infecc Microbiol Clin 26:12-6. 2008
    ..In addition, MVC dose adjustments are advised in patients with renal failure (CLcr <80 ml/min) only if they receive CYP3A4 inhibitors...
  42. doi request reprint New therapies for hepatitis C virus infection
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    Clin Infect Dis 48:313-20. 2009
    ..Herein, the main characteristics of these new antiviral agents and the most important challenges arising with their use--namely, toxicities and rapid selection of resistance--are discussed...
  43. doi request reprint Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe
    Vincent Soriano
    Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    J Infect Dis 198:1337-44. 2008
    ....
  44. ncbi request reprint Management of hepatitis B virus co-infection on and off antiretroviral therapy
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, Calle Sinesio Delgado 10, Madrid 28029, Spain
    Curr HIV/AIDS Rep 5:86-93. 2008
    ..Hopefully, this success will translate into a halt of liver-related complications and death in the co-infected population...
  45. ncbi request reprint Emerging drugs for hepatitis C
    Vincent Soriano
    Hospital Carlos III, Department of Infectious Diseases, Calle Sinesio Delgado 10, Madrid 28029, Spain
    Expert Opin Emerg Drugs 13:1-19. 2008
    ....
  46. doi request reprint Hepatitis delta in HIV-infected individuals in Europe
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    AIDS 25:1987-92. 2011
    ..There is scarce information about the prevalence, epidemiology, virological profile and natural history of hepatitis delta in HIV patients...
  47. ncbi request reprint Prevalence of drug resistance mutations in Spain among both naive and pretreated patients
    V Soriano
    Service of Infectious Diseases, Hospital Carlos III, Instituto de Salud Carlos III, Madrid, Spain
    Antivir Ther 4:57-63. 1999
    ..Two major studies, one in 1997 and another in 1998, have been conducted so far. Global data and results derived from substudies are summarized in this presentation...
  48. ncbi request reprint Impact of chronic liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users
    V Soriano
    Service of Infectious Diseases, Centro de Investigaciones Clinicas, Instituto de Salud Carlos III, Madrid, Spain
    Eur J Epidemiol 15:1-4. 1999
    ..In conclusion, CVLD represents an important cause of hospital admission and death in HIV-infected drug users...
  49. ncbi request reprint Response to interferon-based therapies in HIV-infected patients with chronic hepatitis C due to genotype 4
    Vincent Soriano
    Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    Antivir Ther 10:167-70. 2005
    ..HCV genotype 4 is spreading among European intravenous drug users, who are frequently coinfected with HIV. Information about treatment response in this subset of patients is scarce and conflicting results have been reported...
  50. ncbi request reprint Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, Calle Sinesio Delgado 10, 28029 Madrid, Spain
    AIDS 19:221-40. 2005
  51. ncbi request reprint Long-term follow-up of HIV-infected patients with chronic hepatitis C virus infection treated with interferon-based therapies
    Vincent Soriano
    Service of Infectious Diseases, Hospital Carlos II, Madrid, Spain
    Antivir Ther 9:987-92. 2004
    ..However, the occurrence of liver complications (including hepatocellular carcinoma) and/or HCV relapses in coinfected patients when followed for long periods of time after HCV therapy is not well known...
  52. ncbi request reprint Consensus conference on chronic viral hepatitis and HIV infection: updated Spanish recommendations
    V Soriano
    Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    J Viral Hepat 11:2-17. 2004
    ..These guidelines represent a comprehensive and updated overview on the management of hepatitis B and C in HIV-infected patients...
  53. ncbi request reprint Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin
    Vincent Soriano
    Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    Antivir Ther 9:505-9. 2004
    ..Therefore, extending therapy (for 12 months in HCV genotypes 2/3 and perhaps for 18 months in HCV genotypes 1/4) might be warranted in HIV/HCV-coinfected patients showing EVR...
  54. ncbi request reprint Hepatitis C virus (HCV) relapses after anti-HCV therapy are more frequent in HIV-infected patients
    Vincent Soriano
    Service of Infectious Diseases, Instituto de Salud Carlos III, Madrid, Spain
    AIDS Res Hum Retroviruses 20:351-3. 2004
    ..8% for HCV genotypes 1-4) and/or the use of either standard or pegylated IFN (37% versus 29%, respectively). Thus, extended periods of anti-HCV therapy might reduce HCV relapses in HIV-coinfected patients initially responding to therapy...
  55. ncbi request reprint Hepatitis C and HIV infection: biological, clinical, and therapeutic implications
    V Soriano
    Service of Infectious Diseases, Hospital Carlos III, Instituto de Salud Carlos III Madrid, Spain
    J Hepatol 31:119-23. 1999
    ....
  56. ncbi request reprint Human immunodeficiency virus type 2 (HIV-2) in Portugal: clinical spectrum, circulating subtypes, virus isolation, and plasma viral load
    V Soriano
    Service of Infectious Diseases, Instituto de Salud Carlos III, Madrid, Spain
    J Med Virol 61:111-6. 2000
    ..A lower cellular and plasma viral load with respect to HIV-1 was seen in persons without immunosuppression, from whom the rate of virus recovery was extremely low...
  57. ncbi request reprint Genetic mechanisms of resistance to NRTI and NNRTI
    Vincent Soriano
    Service of Infectious Diseases, Instituto de Salud Carlos III, Madrid, Spain
    HIV Clin Trials 3:237-48. 2002
    ..In respect to nonnucleoside reverse transcriptase inhibitors (NNRTIs), resistance often results from single mutations (K103N is the most frequently found) located at or near the drug pocket binding...
  58. ncbi request reprint Genetic mechanisms of resistance to protease inhibitors and entry inhibitors
    Vincent Soriano
    Service of Infectious Diseases, Instituto de Salud Carlos III, Madrid, Spain
    HIV Clin Trials 3:249-57. 2002
    ..In contrast, agents that target gp41-dependent fusion select for HIV variants with mutations in the gp41 envelope gene...
  59. ncbi request reprint [HIV and HCV coinfection]
    Andres Ruiz-Sancho
    Servicio de Enfermedades Infecciosas, Hospital Carlos III, Madrid, Espana
    Enferm Infecc Microbiol Clin 24:335-45; quiz 346. 2006
    ..Treatment of chronic hepatitis C in HIV1 patients is less efficacious than in HCV-monoinfected individuals and requires particular expertise...
  60. ncbi request reprint [Role of tenofovir in HIV and hepatitis C virus coinfection]
    Paula Tuma
    Servicio de Enfermedades Infecciosas, Hospital Carlos III, Madrid, Espana
    Enferm Infecc Microbiol Clin 26:31-7. 2008
    ..Tenofovir is currently one of the safest nucleos(t)ide analogues, due to its low hepatotoxicity and its lack of negative interference on treatment of HCV infection...
  61. ncbi request reprint Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients
    Pablo Labarga
    Department of Infectious Diseases, Hospital Carlos III, Madrid 28029, Spain
    J Infect Dis 196:670-6. 2007
    ..It is unknown whether sustained HCV clearance after interferon (IFN)-based therapy might reduce this complication...
  62. doi request reprint Preemptive erythropoietin plus high ribavirin doses to increase rapid virological responses in HIV patients treated for chronic hepatitis C
    Eugenia Vispo
    Hospital Carlos III, Madrid, Spain
    AIDS Res Hum Retroviruses 26:419-24. 2010
    ..Extensive intraerythrocyte accumulation of RBV following boosted production of red blood cells by EPO could explain these findings...
  63. doi request reprint [Human immunodeficiency virus infection and viral hepatitis]
    Vicente Soriano
    Servicio de Enfermedades Infecciosas, Hospital Carlos III, Madrid, Espana
    Enferm Infecc Microbiol Clin 29:691-701. 2011
    ..However, interactions between these drugs and antiretroviral agents and the risk of selective resistance pose huge threats in this population...
  64. ncbi request reprint Prevalence of and risk factors for hepatitis B virus infection among street-recruited young injection and non-injection heroin users in Barcelona, Madrid and Seville
    Fernando Vallejo
    Centro Nacional de Epidemiologia, Instituto de Salud Carlos III, Madrid, Espana
    Eur Addict Res 14:116-24. 2008
    ..To evaluate the prevalence of hepatitis B virus (HBV) and associated factors in 949 heroin users (HU): injectors (IHUs) and non-injectors (NIHUs)...
  65. ncbi request reprint Hepatitis B vaccination: an unmet challenge in the era of harm reduction programs
    Fernando Vallejo
    Centro Nacional de Epidemiologia, Instituto de Salud Carlos III, Madrid, Spain
    J Subst Abuse Treat 34:398-406. 2008
    ..The proportion of vaccinated HUs remains very low despite efforts to set up harm reduction programs. New and more active strategies must be incorporated in these programs...
  66. doi request reprint Liver stiffness predicts liver-related complications and mortality in HIV patients with chronic hepatitis C on antiretroviral therapy
    José Vicente Fernández-Montero
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    AIDS 27:1129-34. 2013
    ..Few studies have examined so far the predictive value of liver fibrosis staging on mortality and liver decompensation in HIV/HCV-coinfected patients...
  67. ncbi request reprint HTLV infection among young injection and non-injection heroin users in Spain: prevalence and correlates
    Luis de la Fuente
    Centro Nacional de Epidemiologia, Instituto de Salud Carlos III, C Sinesio Delgado 6, 28029 Madrid, Spain
    J Clin Virol 35:244-9. 2006
    ....
  68. ncbi request reprint Poor validity of self-reported HBV vaccination among young heroin users in Spain supports the policy "don't ask, draw a blood sample, vaccinate and try to schedule another visit"
    Luis de la Fuente
    Centro Nacional de Epidemiologia, Instituto de Salud Carlos III, Madrid, C Sinesio Delgado 6, 28029 Madrid, Spain
    J Clin Virol 38:87-90. 2007
    ..To assess the validity of self-reported hepatitis B virus vaccination status in young heroin users...
  69. ncbi request reprint [Resistance in hepatitis B virus]
    Julie Sheldon
    Servicio de Enfermedades Infecciosas, Hospital Carlos III, Madrid, Espana
    Enferm Infecc Microbiol Clin 26:49-55. 2008
    ..The characterization of the resistance mutations is helpful for the prevention and the optimization of antiviral therapies...
  70. doi request reprint HIV protease inhibitors: recent clinical trials and recommendations on use
    José Vicente Fernández-Montero
    Hospital Carlos III, Department of Infectious Diseases, Madrid, Spain
    Expert Opin Pharmacother 10:1615-29. 2009
    ..PIs have evolved over the years to gain in potency, convenience, tolerability and genetic barrier to resistance...
  71. ncbi request reprint Impact of drug levels and baseline genotype and phenotype on the virologic response to amprenavir/ritonavir-based salvage regimens
    Luisa Valer
    Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    AIDS Patient Care STDS 18:1-6. 2004
    ..In summary, HIV genotyping but not drug levels might be helpful to predict which patients would benefit from a rescue intervention based on APV/RTV 600/100 twice daily...
  72. ncbi request reprint Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir
    Eugenia Vispo
    Hospital Carlos III, Madrid, Spain
    Antivir Ther 13:429-37. 2008
    ..There is little information about the influence of antiretroviral drugs on the antiviral activity of pegylated interferon (PEG-IFN) plus ribavirin (RBV) against hepatitis C virus (HCV)...
  73. ncbi request reprint Hepatic and renal safety profile of tenofovir in HIV-infected patients with hepatitis C, including patients on interferon plus ribavirin
    Matilde Sanchez-Conde
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    HIV Clin Trials 6:278-80. 2005
    ..Signs of tubular dysfunction in blood or urine were not recognized in 17 HCV-HIV co-infected patients exposed to TDF during interferon plus ribavirin therapy...
  74. ncbi request reprint [Advances in the diagnosis and treatment of the infection by the hepatitis B virus]
    Marina Nunez
    Servicio de Enfermedades Infecciosas, Hospital Carlos III, Madrid, Spain
    Enferm Infecc Microbiol Clin 22:539-49. 2004
    ..While the selection of lamivudine resistance mutations is frequent, adefovir has a high genetic barrier. HIV infection negatively impacts on HBV disease, requiring these coinfected patients strategies aimed to manage both viruses...
  75. doi request reprint The role of injection versus socioeconomic factors in hepatitis A virus infection among young heroin users: Implications for vaccination policies
    Francisco J Luquero
    Centro Nacional de Epidemiologia, Instituto de Salud Carlos III, Madrid, Spain European Programme for Intervention Epidemiology Training EPIET, European Centre for Disease Prevention and Control ECDC, Stockholm, Sweden
    Vaccine 27:2674-9. 2009
    ..Consequently, HAV vaccination should be recommended not only in IDUs but also in non-IDUs depending on their socioeconomic characteristics...
  76. doi request reprint Analysis of IL28B alleles with virologic response patterns and plasma cytokine levels in HIV/HCV-coinfected patients
    Amanda Fernandez-Rodriguez
    Unidad de coinfección HIV hepatitis, Centro Nacional de Microbiologia, Instituto de Salud Carlos III, 28220 Majadahonda, Madrid, Spain
    AIDS 27:163-73. 2013
    ..We also explore the behavior of plasma cytokine levels...
  77. doi request reprint Fosamprenavir (GW433908)/ritonavir in HIV-infected patients: efficacy and safety results from the Spanish Expanded Access Program
    M Jesús Pérez-Elías
    Hospital Ramon y Cajal, Madrid, Spain
    Enferm Infecc Microbiol Clin 27:28-32. 2009
    ..The objective of this study was to collect safety data on treatment with fosamprenavir/ritonavir (FPV/r) 700/100mg BID in HIV-infected patients through an expanded access program...
  78. ncbi request reprint Virological outcome of chronic hepatitis B virus infection in HIV-coinfected patients receiving anti-HBV active antiretroviral therapy
    Marina Nunez
    Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    AIDS Res Hum Retroviruses 22:842-8. 2006
    ..Thus, HBV/HIV-coinfected patients might benefit from an earlier introduction of HAART...
  79. ncbi request reprint Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C
    Luz Martin-Carbonero
    Hospital Carlos III, CIBERehd, Madrid, Spain
    AIDS 22:15-21. 2008
    ..It is unclear whether this applies to HIV/HCV-co-infected patients...
  80. doi request reprint Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies
    Lourdes Anta
    Infectious Diseases Department, Hospital Carlos III, Madrid, Spain
    AIDS 27:81-5. 2013
    ..It displays in-vitro activity extending over other NNRTI-resistant HIV strains. There is scarce information about the rate of RPV resistance-associated mutations (RAMs) in patients failing other NNRTIs...
  81. doi request reprint [Viral resistance and genetic barrier of atazanavir]
    Carmen de Mendoza
    Servicio de Enfermedades Infecciosas, Hospital Carlos III, Madrid, Espana
    Enferm Infecc Microbiol Clin 26:28-33. 2008
    ..Despite having a moderate genetic barrier when not boosted with ritonavir, the prolonged half life of ATV minimises the risk of resistance in clinical practice...
  82. pmc Injecting and HIV prevalence among young heroin users in three Spanish cities and their association with the delayed implementation of harm reduction programmes
    Luis de la Fuente
    Centro Nacional de Epidemiologia, Instituto, de Salud Carlos III, Madrid, C Sinesio Delgado 6, 28029 Madrid, Spain
    J Epidemiol Community Health 60:537-42. 2006
    ..To evaluate changes in the prevalence of HIV infection among young heroin users in three Spanish cities, and their association with harm reduction programmes (HRPs)...
  83. ncbi request reprint Management of chronic hepatitis C in patients co-infected with HIV: focus on safety considerations
    Miriam Romero
    Gastroenterology and Hepatology Department, Hospital Carlos III, Instituto de Salud Carlos III, Madrid, Spain
    Drug Saf 27:7-24. 2004
    ..New IFN formulations (e.g. pegylated interferon) plus ribavirin appear to be way of the future for the treatment of chronic hepatitis C in patients both with and without HIV co-infection...
  84. doi request reprint Liver complications have reached a plateau as cause of hospital admission and death in HIV patients in Madrid
    Carla Núñez-Fernández
    Infectious Diseases Department, Hospital Carlos III, Madrid, Spain
    AIDS Res Hum Retroviruses 25:383-5. 2009
    ..Hepatic complications are currently still responsible for 8.7% of all hospital admissions and one-third of in-hospital deaths, with hepatitis C virus infection by far the leading etiologic agent...
  85. ncbi request reprint Baseline serum hepatitis C virus (HCV) RNA level and response at week 4 are the best predictors of relapse after treatment with pegylated interferon plus ribavirin in HIV/HCV-coinfected patients
    Marina Nunez
    Department of Infectious Diseases Hospital Carlos III, Calle Sinesio Delgado 10, 28029 Madrid, Spain
    J Acquir Immune Defic Syndr 45:439-44. 2007
    ..Relapse after achieving virologic response to anti-hepatitis C virus (HCV) treatment considerably reduces sustained virologic response rates. It is unclear what the main predictors of relapse in HCV/HIV-coinfected patients are...
  86. ncbi request reprint Characteristics and prospects for hepatitis C therapy of an HIV-HCV coinfected population followed at a reference HIV center
    Ivana Maida
    Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    HIV Clin Trials 6:329-36. 2005
    ..A cross-sectional study was performed during 2004 at a large HIV clinic in Spain to identify HIV-HCV coinfected individuals who might be candidates for HCV therapy...
  87. doi request reprint Prevalence and risk factors associated with pulmonary hypertension in HIV-infected patients on regular follow-up
    Maribel Quezada
    Department of Cardiology, Hospital Ramon y Cajal, Madrid, Spain
    AIDS 26:1387-92. 2012
    ..Transthoracic echocardiography (TTE) is a noninvasive tool validated for PAH screening. The aim of our study was to establish the prevalence and factors associated with PAH in HIV-infected patients...
  88. ncbi request reprint [Diagnosis of HIV-1 non-B subtypes and HIV-2]
    Carlos Toro
    Servicio de Microbiologia, Hospital Carlos III, Madrid, Espana
    Enferm Infecc Microbiol Clin 26:66-70. 2008
    ..The availability of both in vitro and clinical data from studies of HIV-1 non-B subtypes will improve the performance of bioinformatics tools...
  89. ncbi request reprint Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine
    Marina Nunez
    Service of Infectious Diseases, Instituto de Salud Carlos III, Madrid, Spain
    AIDS 16:2352-4. 2002
    ..HBV-DNA levels dropped a median of 3.78 logs from baseline to 24 weeks. Tenofovir was very effective at reducing HBV-DNA levels in HIV/HBV-co-infected patients carrying either wild-type or lamivudine-resistant viruses...
  90. doi request reprint Influence of a single nucleotide polymorphism at the main ribavirin transporter gene on the rapid virological response to pegylated interferon-ribavirin therapy in patients with chronic hepatitis C virus infection
    Judit Morello
    Laboratory of Pharmacology, Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    J Infect Dis 202:1185-91. 2010
    ....
  91. ncbi request reprint Treatment of chronic hepatitis B in the human immunodeficiency virus-infected patient: present and future
    Marina Nunez
    Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    Clin Infect Dis 37:1678-85. 2003
    ..Preliminary results with some of them are quite promising and probably will widen the therapeutic armamentarium against hepatitis B in patients with HIV infection...
  92. pmc Plasma ribavirin trough concentrations at week 4 predict hepatitis C virus (HCV) relapse in HIV-HCV-coinfected patients treated for chronic hepatitis C
    Judit Morello
    Laboratory of Pharmacology, Hospital Carlos III, 28029 Madrid, Spain
    Antimicrob Agents Chemother 54:1647-9. 2010
    ..5 microg/ml (4.5 [1.3 to 15.5]), baseline serum HCV RNA (2.5 [1.2 to 5.1]), and HCV genotype 1 or 4 (13.3 [2.6 to 66.7]). Monitoring of RBV C(trough) may permit early adjustment of RBV dosage to avoid HCV relapse...
  93. ncbi request reprint Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial
    Marina Nunez
    Department of Infectious Diseases, Hospital Carlos III, Calle Sinesio Delgado 10, Madrid 28029, Spain
    AIDS Res Hum Retroviruses 23:972-82. 2007
    ..The use of RBV 1000-1200 mg/day plus pegIFN is relatively safe and provides SVR in nearly half of coinfected patients, twice as high in HCV-2/3 than HCV-1/4...
  94. ncbi request reprint Correlation between rules-based interpretation and virtual phenotype interpretation of HIV-1 genotypes for predicting drug resistance in HIV-infected individuals
    Oscar Gallego
    Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    J Virol Methods 121:115-8. 2004
    ..The inclusion of additional sequences in the VircoNET database, mainly those derived from heavily treatment-experienced patients and/or from patients failing the most recently approved drugs might improve its performance...
  95. ncbi request reprint Treatment of chronic hepatitis B in HIV-infected patients in 2007
    Pilar Garcia-Gasco
    Department of Infectious Diseases, Hospital Carlos III, Calle Sinesio Delgado 10, Madrid 28029, Spain
    J HIV Ther 12:19-23. 2007
  96. ncbi request reprint Predictors of virological response to atazanavir in protease inhibitor-experienced patients
    Ana Barrios
    Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    HIV Clin Trials 5:201-5. 2004
    ..Atazanavir (ATV) is the latest approved HIV protease inhibitor (PI). Even though it is very convenient (only two capsules once a day), concerns have risen about its potency...
  97. ncbi request reprint Rate of virologic failure and selection of drug resistance mutations using different triple nucleos(t)ide analogue combinations in HIV-infected patients
    Luz Martin-Carbonero
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    AIDS Res Hum Retroviruses 22:1231-5. 2006
    ..The presence of TAMs precluded the selection of K65R in patients treated with TDF. Resistance pathways for TDF and thymidine analogues seem to be divergent and could be the basis to explore a synergism between these drugs...
  98. ncbi request reprint Performance of six different ritonavir-boosted protease inhibitor-based regimens in heavily antiretroviral-experienced HIV-infected patients
    Carmen de Mendoza
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    HIV Clin Trials 7:163-71. 2006
    ..Regimens based on ritonavir-boosted protease inhibitors (PI/r) are often used as rescue interventions. It is unclear whether significant differences exist between distinct PI/r...
  99. ncbi request reprint Effectiveness and safety of abacavir, lamivudine, and zidovudine in antiretroviral therapy-naive HIV-infected patients: results from a large multicenter observational cohort
    Juan Berenguer
    Infectious Diseases and HIV Unit, Hospital Gregorio Maranon, Madrid, Spain
    J Acquir Immune Defic Syndr 41:154-9. 2006
    ..To analyze the safety and effectiveness of abacavir, lamivudine, and zidovudine (ABC/3TC/ZDV) in antiretroviral therapy (ART)-naive HIV-infected patients...
  100. ncbi request reprint [Adaptive cell immune response against the hepatitis C virus infection]
    Norma Ibón Rallón
    Laboratorio de Biologia Molecular, Servicio de Enfermedades Infecciosas, Hospital Carlos III, Madrid, Espana
    Med Clin (Barc) 129:469-76. 2007
    ..An integral interpretation of the numerous experimental findings may allow a better understanding of the immune mechanisms involved in the inability of the immune system to successfully control chronic HCV infection...
  101. doi request reprint [Recruitment methodology and characteristics of a cohort of young regular cocaine users in three Spanish cities (the Itinere-cocaine Project)]
    Jose Pulido
    Centro Nacional de Epidemiologia, Instituto de Salud Carlos III, Madrid, Espana
    Gac Sanit 23:200-7. 2009
    ..We describe the recruitment methodology and characteristics of a cohort of young cocaine users...